RxDoctor Payments Data

Jessica Albritton

Family · Wesley Chapel, FLNPI 1538872916

Payments from drug & device makers

$3,211in general payments, 2019–2025

Across 166 payments — averaging $19.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Teva Pharmaceuticals USA, Inc.$406
  • Pfizer$335
  • UCB, Inc.$249
  • Lundbeck LLC$213
  • Neurocrine Biosciences, Inc.$167
  • plus $804 from 12 others

What the payments were for

  • Food & beverage$3,211100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,211 in reported general payments places this provider in the 85th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$4,997
Medicare patients
41
Services billed
46

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe33$30,454
UbrelvyUbrogepant23$24,301
BriviactBrivaracetam12$18,236
Nurtec OdtRimegepant Sulfate15$13,893
Ajovy AutoinjectorFremanezumab-Vfrm16$11,294
Memantine Hcl146$3,346
Memantine Hcl ErMemantine Hcl21$2,290
Carbidopa-Levodopa ErCarbidopa/Levodopa15$1,977
Levetiracetam55$1,612
Divalproex Sodium19$1,068
Carbamazepine18$949
Carbidopa-LevodopaCarbidopa/Levodopa80$936
Divalproex Sodium ErDivalproex Sodium43$825
Primidone29$779
Oxcarbazepine14$779

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$1,036$24,30123 claims
UCB, Inc.Briviact$249$18,23612 claims
PfizerNurtec Odt$335$13,89315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 14,618 family providers in Florida.

Other family in Wesley Chapel

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →